Back to top

BioCryst (BCRX) Posts Strong Q2 Earnings, Maintains 2025 Revenue Outlook

BioCryst (BCRX) Posts Strong Q2 Earnings, Maintains 2025 Revenue Outlook

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BioCryst Pharmaceuticals, Inc. (BCRX)